Semaglutide and canagliflozin combination significantly reduces UACR in early diabetic kidney disease

Diabetic kidney disease (DKD) is a severe complication of type 2 diabetes mellitus (T2DM), often progressing to end-stage renal disease. Early DKD is characterized by metabolic dysfunction, albuminuria, and chronic low-grade inflammation. While SGLT2 inhibitors and GLP-1 receptor agonists are known for their renoprotective and metabolic benefits individually, there's limited evidence on their combined efficacy in early DKD. This gap highlights the need for strategies that target multiple facets of DKD progression.

This randomized controlled trial enrolled 120 patients with early-stage DKD, allocating them (1:1:1:1) to four groups (n = 30 each): canagliflozin 100 mg orally once daily, semaglutide 0.25 mg once weekly (escalating to 1.0 mg after 4 weeks), combination therapy, or placebo/control. All participants received standard background care for 24 weeks. Primary renal outcomes were urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). Secondary outcomes included HbA1c, fasting glucose, HOMA-IR, lipid profiles, and inflammatory biomarkers like TNF-α, IL-6, and CRP.

At 24 weeks, combination therapy of semaglutide and canagliflozin achieved significantly greater reductions in UACR compared with either monotherapy or placebo (P < 0.05). This suggests a synergistic effect on albuminuria, a key marker of kidney damage. Across all treatment groups, a small reduction in eGFR was observed, but there were no significant differences between groups, indicating renal function stability. Metabolic and inflammatory markers also showed superior improvements with combination therapy: HbA1c, fasting glucose, HOMA-IR, lipid parameters, and inflammatory markers (TNF-α, IL-6, CRP) all demonstrated better results in the combination therapy group compared to single-agent therapy (P < 0.05). This comprehensive improvement underscores the multifaceted benefits of the combined approach on glycemic control, insulin sensitivity, lipid profiles, and systemic inflammation.